HMG Peptide Has Decades of Fertility Trials. Men's Use Has None.

Human menopausal gonadotropin, sold under the clinical name menotropin and marketed online simply as “HMG,” is one of the most thoroughly trial-tested compounds you will find on a research-peptide storefront. It has been compared against recombinant FSH in randomized controlled trials for ovarian stimulation since before most of the vendors selling it were incorporated, with a 2011 Cochrane review alone pooling 42 such trials and 9,606 couples from a literature search running back to 1966.^[1] That is not the profile of an obscure research chemical. It is the profile of a decades-old reproductive endocrinology drug.

The problem is that almost nobody buying HMG from a peptide vendor is trying to conceive through IVF. Most are men hoping it will restart sperm production after testosterone replacement therapy or anabolic steroid use shut it down, and that specific question, the one the market cares about, has close to none of the trial evidence behind it that the female-fertility indication does. HMG’s story is not “an unstudied peptide.” It is a well-studied drug being pointed at a question its own evidence base was never built to answer.

What the human evidence on HMG covers

The clinical trial record for HMG is almost entirely a women’s fertility record. Reproductive endocrinologists have run head-to-head comparisons against recombinant FSH for controlled ovarian stimulation in IVF and ICSI cycles for decades, and the largest pooled analysis of that work, the 2011 Cochrane review mentioned above, found no significant difference in live birth rate between recombinant FSH and urinary gonadotropins including HMG (odds ratio 0.97, 95% CI 0.87 to 1.08).^[1]

That finding matters for anyone comparing HMG to the newer recombinant products. The Cochrane authors concluded the two perform similarly enough that the choice should come down to cost and convenience rather than efficacy, a point worth returning to later.

The off-label use driving most retail interest, restoring sperm production in men whose natural testosterone production has been suppressed by TRT or anabolic steroids, sits on a completely different evidentiary footing. A 2022 review of this exact clinical problem found only limited prospective randomized data on hormonal stimulation in that setting, with most of what exists coming from observational studies on spontaneous recovery after drug cessation rather than controlled trials of gonadotropin therapy itself.^[2]

42 randomized trials pooled in the Cochrane review comparing hMG to recombinant FSH PMID 21328276

So the honest summary is a split one. Ask “does HMG work for ovarian stimulation,” and you are standing on 50 years of accumulated RCT evidence. Ask “does HMG restart sperm production after steroid use,” and you are standing on case reports.

Mechanism: what HMG supplies that recombinant FSH doesn’t

Part of why HMG gets lumped in with research peptides like BPC-157 or GHK-Cu is marketing. The pharmacology doesn’t support the grouping. Unlike recombinant FSH, which supplies only follicle-stimulating hormone activity, highly purified human menopausal gonadotropin also carries luteinizing hormone activity, a difference that has been the subject of head-to-head trials against recombinant FSH alone.^[3]

In women, the mechanism is settled textbook endocrinology. The two-cell, two-gonadotrophin model describes it cleanly: FSH acts on granulosa cells to drive follicular development, while LH drives thecal-cell androgen synthesis that feeds those same follicles, a division of labor established in reproductive endocrinology for decades.^[4]

The male-side mechanism is where this article has to be careful. The standard assumption behind every off-label regimen is that the same LH-like activity supports testosterone production in Leydig cells, while FSH signals to Sertoli cells to help restart spermatogenesis. That is the physiology every vendor page and forum post repeats as settled fact.

It is also the one piece of this argument I could not pin to a dedicated citation strong enough to stand next to the female-side mechanism work above. The male mechanism is plausible and widely assumed, but it rests on inference rather than on the same tier of established, specifically-cited physiology that backs the female side.

Even the question of whether HMG’s extra LH activity does anything useful remains debated inside reproductive medicine itself. A meta-analysis of 56 randomized trials and 14,034 women found that gonadotropins with LH activity probably result in little to no difference in live birth (relative risk 1.07, 95% CI 0.96 to 1.18) compared with recombinant FSH alone.^[3]

The striking part isn’t the drug. It’s the certainty. Few compounds sold as “research peptides” have a 42-trial Cochrane meta-analysis behind them.^[1] HMG is one of them, for a question most buyers aren’t asking.

Dosing as published

Here is where the two populations diverge hardest.

For women undergoing controlled ovarian stimulation, published dosing is not a fixed number. It is a moving target, adjusted cycle by cycle against hormone levels and follicle counts, which is precisely why no single daily-dose figure survived this article’s fact-check. Protocols vary by indication, ovarian reserve, and response, and the clinical literature treats “the dose” as something a reproductive endocrinologist titrates in real time, not a quantity a self-injecting buyer can look up.

For men, the published regimens come almost entirely from congenital hypogonadotropic hypogonadism. Steroid-recovery use is a different population that these trials did not enroll. A 2025 systematic review covering 50 studies and 1,583 men with that condition found combined gonadotropin therapy took a mean of about 12 months to induce measurable spermatogenesis and about 19 months to reach pregnancy, with sperm parameters checked periodically rather than on any fixed schedule.^[5]

• What’s published: dosing and duration data for congenital hypogonadotropic hypogonadism, a population with a different underlying cause than steroid-induced suppression.
• What’s not published: any trial establishing a standard HMG dose or duration specifically for men recovering fertility after anabolic steroid use.
• What that means practically: anyone following a steroid-forum “HMG protocol” is extrapolating from a different patient population. Nobody has tested that protocol in the population using it.

Where the hMG evidence lives

Evidence depth by population and clinical question.

Tesamorelin’s dosing landscape shows the same split: a well-studied clinical dose sitting next to a self-use market that never ran its own trial.

Side effects and red flags

The adverse-event profile that exists is, again, almost entirely a women’s fertility profile.

• Ovarian hyperstimulation syndrome is a recognized complication of gonadotropin-stimulated cycles, ranging from mild to moderate and severe forms, with the severe form requiring specific hospital-level management.^[6]
• Monitoring is how OHSS gets managed. Clinical guidelines define monitoring protocols during the stimulation cycle specifically to catch and reduce that risk, a safeguard that self-injection outside a clinic simply does not replicate.^[7]
• Multiple pregnancy risk is substantial. Ovarian stimulation used alone, the kind of cycle HMG drives, is associated with roughly an eightfold higher risk of multiple pregnancy compared with natural conception (pooled relative risk 8.80, 95% CI 5.09 to 15.20) in a systematic review of 63 studies.^[8]

8.8x higher risk of multiple pregnancy with ovarian stimulation vs. natural conception PMID 27484228

The monitoring is the treatment. OHSS is managed by catching it early through scans and bloodwork during the cycle.^[7] Nothing in the vial itself does that job. Buy the hormone without the clinic and you keep the risk while discarding the safeguard that made the trials safe.

For men self-administering HMG outside clinical supervision, there is no equivalent safety record at all. No published trial has systematically collected adverse-event data for that specific use, which means the risk profile for the population buying this drug online is, functionally, unknown.

Where HMG sits against its alternatives

Inside reproductive medicine, the comparisons are settled enough to be boring. Meta-analyses comparing HMG with recombinant FSH in IVF have not found a consistent live-birth advantage for either formulation, which is why the Cochrane review’s own authors concluded the clinical choice between them should depend on availability, convenience, and cost rather than efficacy.^[1]

For male hypogonadotropic hypogonadism, the comparison that matters is HMG-containing combined therapy against hCG alone, and here the newer evidence has an answer: that 2025 systematic review of 1,583 men found combined gonadotropin therapy, hCG plus FSH or HMG, more effective than hCG monotherapy at restoring spermatogenesis, with a pooled success rate of 74%.^[5]

ARA-290 is the closest thing to a fair comparison among research-peptide-market compounds, and even that comparison undersells HMG. ARA-290’s trials are small early-phase studies. HMG has multiple Cochrane-level meta-analyses, tens of thousands of patients, and half a century of accumulated data behind the indication it was built for. Set it next to GHK-Cu, which has no comparable trial base in any of its marketed uses, and the real gap in HMG’s case is the mismatch between where the evidence sits and where the money is being spent.

A randomized trial testing HMG-based regimens specifically in men recovering fertility after anabolic steroid use, rather than in men with congenital hypogonadism, has not been published. Until one is, every “HMG protocol” circulating in steroid-forum post-cycle-therapy threads is a borrowed inference from a different patient population, dressed up as a tested one.

Bottom line: HMG is not an unstudied peptide. It is a thoroughly studied fertility drug, pressed into service for a question none of its studies ever asked, and sold without the monitoring that made the original studies safe.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.